01933nas a2200373   4500000000100000008004100001260001300042653001500055653001000070653001000080653002100090653001500111653001100126653001100137653001100148653002300159653001200182653002500194653000900219653001500228653002500243653001500268653002800283653001800311100001500329700001500344700001200359245009000371856005400461300001100515490000700526520101200533022001401545       2011                            d  c2011 Jul10aAdolescent10aAdult10aChild10aChild, Preschool10aDemography10aFemale10aHawaii10aHumans10aLeprostatic Agents10aleprosy10aLongitudinal studies10aMale10aMicronesia10aMycobacterium leprae10aPrevalence10aTransients and Migrants10aUnited States1 aWoodall PA1 aScollard D1 aRajan L00aHansen disease among Micronesian and Marshallese persons living in the United States.  uhttp://www.cdc.gov/eid/content/17/7/pdfs/1202.pdf  a1202-80 v173 a<p>An increasing proportion of Hansen disease cases in the United States occurs among migrants from the Micronesian region, where leprosy prevalence is high. We abstracted surveillance and clinical records of the National Hansen's Disease Program to determine geographic, demographic, and clinical patterns. Since 2004, 13% of US cases have occurred in this migrant population. Although Hawaii reported the most cases, reports have increased in the central and southern states. Multibacillary disease in men predominates on the US mainland. Of 49 patients for whom clinical data were available, 37 (75%) had leprosy reaction, neuropathy, or other complications; 17 (37%) of 46 completed treatment. Comparison of data from the US mainland with Hawaii and country-of-origin suggests under-detection of cases in pediatric and female patients and with paucibacillary disease in the United States. Increased case finding and management, and avoidance of leprosy-labeled stigma, is needed for this population.</p>  a1080-6059